Abstract
standard care for symptom relief in patients with Barrett’s oesophagus (BO). 3 In our study, 94% of the BO patients were treated with PPIs. Among BO patients, PPIs may decrease the risk of progression to high-grade dysplasia or oesophageal adenocarcinoma (OAC). 4 We do not know to what extent PPIs protect against new development of BO among patients with gastro-oesophageal reflux disease. 5 In the general population, the incidence of PPI use increased between 2000 and 2012 by 45% in the United Kingdom (UK) and 60% in the Netherlands. The incidence of BO levelled off as described both in the UK and Netherlands. The incidence of OAC among BO patients nevertheless increased more than 3-fold over the same time period. The design of our study and the use of PPIs by nearly all BO patients do not allow us to draw any conclusions as to what extent PPI use influenced the incidence of BO or OAC. It may well be that the increase in PPI use in the population contributed to the stabilisation of the incidence of BO and that the current PPI use by nearly all BO patients moderated the increase in OAC incidence. However, these hypotheses remain speculative.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.